Eli Lilly Halts Phase III Trial of DLBCL Drug

Pharmaceutical giant Eli Lilly announced that it is halting the development of the experimental drug enzastaurin after it failed a Phase III trial assessing it as monotherapy for some patients with diffuse large B-cell lymphoma (DLBCL).

Eli Lilly had hoped that the phase III PRELUDE trial would show the efficacy of enzastaurin in the prevention of relapse in patients with DLBCL. Unfortunately, data indicated that the drug failed to show a statistically significant increase compared to placebo in disease-free survival in patients considered to be at high risk relapse following rituximab-based chemotherapy.

On the bright side, safety data was consistent with previous studies of the drug (also known as LY317615 HCl) and no new safety issues came up during the trial.

Fifth Eli Lilly drug trial to fail in past year

The company will present the Phase III data at an upcoming scientific meeting. The failure of enzastaurin amounts to the fifth drug failure for Eli Lilly in the past year.

Said Richard Gaynor, M.D., vice president of product development and medical affairs for Lilly Oncology:

We are disappointed in the results that we're announcing today … However, our oncology pipeline is still one of the most robust across the industry containing more than 20 molecules, including two Phase III molecules in five different tumor types.

Enzastaurin is believed to work by acting as a serine/threonine kinase inhibitor of the PKC beta and AKT pathways.

Source: Lilly Oncology

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap